NASDAQ:QDEL - Quidel Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $67.39 -0.24 (-0.35 %) (As of 03/19/2019 04:00 PM ET)Previous Close$67.63Today's Range$67.31 - $68.0852-Week Range$44.27 - $77.63Volume130,506 shsAverage Volume255,799 shsMarket Capitalization$2.66 billionP/E Ratio23.90Dividend YieldN/ABeta1.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California. Receive QDEL News and Ratings via Email Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:QDEL Previous Symbol CUSIP74838J10 CIK353569 Webwww.quidel.com Phone858-552-1100Debt Debt-to-Equity Ratio0.12 Current Ratio1.21 Quick Ratio0.79Price-To-Earnings Trailing P/E Ratio23.90 Forward P/E Ratio24.33 P/E Growth0.99 Sales & Book Value Annual Sales$522.28 million Price / Sales5.09 Cash Flow$4.5289 per share Price / Cash Flow14.88 Book Value$10.82 per share Price / Book6.23Profitability EPS (Most Recent Fiscal Year)$2.82 Net Income$74.18 million Net Margins14.20% Return on Equity31.73% Return on Assets14.87%Miscellaneous Employees1,224 Outstanding Shares39,447,000Market Cap$2.66 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Quidel (NASDAQ:QDEL) Frequently Asked Questions What is Quidel's stock symbol? Quidel trades on the NASDAQ under the ticker symbol "QDEL." How were Quidel's earnings last quarter? Quidel Co. (NASDAQ:QDEL) issued its quarterly earnings results on Wednesday, February, 13th. The company reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.21. The company had revenue of $132.59 million for the quarter, compared to analyst estimates of $132.26 million. Quidel had a return on equity of 31.73% and a net margin of 14.20%. The company's quarterly revenue was up 15.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.56 earnings per share. View Quidel's Earnings History. When is Quidel's next earnings date? Quidel is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Quidel. What price target have analysts set for QDEL? 6 equities research analysts have issued 12-month target prices for Quidel's shares. Their predictions range from $63.00 to $80.00. On average, they anticipate Quidel's stock price to reach $72.80 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for Quidel. What is the consensus analysts' recommendation for Quidel? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quidel. Has Quidel been receiving favorable news coverage? Press coverage about QDEL stock has been trending somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quidel earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Quidel's key competitors? Some companies that are related to Quidel include Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and ImmuCell (ICCC). What other stocks do shareholders of Quidel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include Netflix (NFLX), Intel (INTC), Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Energy Transfer LP Unit (ET), Cornerstone Total Return Fund (CRF), Cisco Systems (CSCO), General Electric (GE) and Advanced Micro Devices (AMD). Who are Quidel's key executives? Quidel's management team includes the folowing people: Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)Mr. Randall J. Steward, Chief Financial Officer (Age 65)Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 51)Dr. Werner Kroll, Sr. VP of R&D (Age 62)Mr. Edward Keith Russell, Sr. VP of North America Commercial Operations (Age 51) Who are Quidel's major shareholders? Quidel's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.86%), Macquarie Group Ltd. (2.42%), Dimensional Fund Advisors LP (2.19%), Dimensional Fund Advisors LP (2.18%), New York State Common Retirement Fund (1.90%) and Norges Bank (1.81%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel. Which institutional investors are selling Quidel stock? QDEL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bank of New York Mellon Corp, Two Sigma Investments LP, Gotham Asset Management LLC, First Trust Advisors LP, Chartwell Investment Partners LLC, Crown Advisors Management Inc. and Eagle Asset Management Inc.. Company insiders that have sold Quidel company stock in the last year include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski and Thomas D Brown. View Insider Buying and Selling for Quidel. Which institutional investors are buying Quidel stock? QDEL stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, AMI Asset Management Corp, Bellevue Group AG, Gagnon Securities LLC, Massachusetts Financial Services Co. MA, SG Americas Securities LLC, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Quidel. How do I buy shares of Quidel? Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quidel's stock price today? One share of QDEL stock can currently be purchased for approximately $67.39. How big of a company is Quidel? Quidel has a market capitalization of $2.66 billion and generates $522.28 million in revenue each year. The company earns $74.18 million in net income (profit) each year or $2.82 on an earnings per share basis. Quidel employs 1,224 workers across the globe. What is Quidel's official website? The official website for Quidel is http://www.quidel.com. How can I contact Quidel? Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected] MarketBeat Community Rating for Quidel (NASDAQ QDEL)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 321 (Vote Outperform)Underperform Votes: 275 (Vote Underperform)Total Votes: 596MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What causes a recession?